The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease

Bibliography

• Siddiqui MF, Rast S, Lynn MJ, et al. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Parkinsonism Relat Disord 2002;8(4):277-84
   PubMed Web of Science ®Google Scholar
• Khedr Em, EL Fetoh NA, Khalifa H, et al. Prevalance of non motor features in a cohort of Parkinson’s disease patients. Clin Neurol Neurosurg 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P. The importance of non-motor disturbances to quality of life in Parkinson’s disease. J Neurol Sci 2011;310(1-2):12-16
   PubMed Web of Science ®Google Scholar
• Sung HY, Park JW, Kim JS. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease. J Mov Disord 2014;7(1):7-12
   Google Scholar
• Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 2013;260(5):1332-8
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson’s Disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J Neurol Sci 2012;319(1-2):86-8
   PubMed Web of Science ®Google Scholar
• Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 2014;20(5):535-40
   PubMed Web of Science ®Google Scholar
• Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric Emptying in Parkinson ’s disease. Mov Disord 2014;29(1):23-32
   PubMed Web of Science ®Google Scholar
• Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;396(1):67-72
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson’s disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci 2012;313(1-2):57-63
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non motorsymptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotorsymptoms questionnaire in 545 patients. Mov Disord 2007;22(11):1623-9
   PubMed Web of Science ®Google Scholar
• Park H, Lee JY, Shin CM, et al. Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. Parkinsonism Relat Disord 2015;21(5):455-60
   PubMed Web of Science ®Google Scholar
• Sommers T, Corban C, Sengupta N, et al. Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol 2015;110(4):572-9
   PubMed Web of Science ®Google Scholar
• Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. 2009;73(21):1752-8
   Google Scholar
• Parkman H, Hasler W, Fisher R. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-622
   PubMed Web of Science ®Google Scholar
• Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2012;18(5):433-40
   PubMed Web of Science ®Google Scholar
• Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43(11):2398-404
   PubMed Web of Science ®Google Scholar
• Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci 1986;31:147-62
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999;94(5):1327
   PubMed Web of Science ®Google Scholar
• Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 2013;4(5):223-31
   PubMedGoogle Scholar
• Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2011;26(5):889-92
   PubMed Web of Science ®Google Scholar
• Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract 2013;28:289-99
   PubMed Web of Science ®Google Scholar
• Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010;24(4):943-59
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 2013;28(9):1241-9
   PubMed Web of Science ®Google Scholar
• Fasano A, Bove F, Gabrielli M, et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin Neuropharmacol 2014;37(4):91-5
   PubMed Web of Science ®Google Scholar
• Barboza JL, Talley NJ, Moshiree B. Current and emerging pharmacotherapeutic options for irritable bowel syndrome. Drugs 2014;74(16):1849-70
   PubMed Web of Science ®Google Scholar
• Ashraf W, Park F, Lof J, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 1995;9(6):639-47
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord 1997;12(6):946-51
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 2007;22(9):1239-44
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349(14):1360-8
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25(11):1351-61
   PubMed Web of Science ®Google Scholar
• Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology 2012;78(21):1650-4
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35(5):587-99
   PubMed Web of Science ®Google Scholar
• Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365(6):527-36
   PubMed Web of Science ®Google Scholar
• Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2(9):796-805
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation--a European perspective. Neurogastroenterol Motil 2011;23(8):697-710
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20(6):680-6
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358(22):2344-54
   PubMed Web of Science ®Google Scholar
• Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil 2015; Epub ahead of prin
   Google Scholar
• Tegaserod maleate Information. Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm103223.htm 2012. [Last assessed April 2015]
   Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35(7):745-67
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol 2014;7(4):167-75
   PubMed Web of Science ®Google Scholar
• Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 2011;141:486-98
   PubMed Web of Science ®Google Scholar
• Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33(4):429-40
   PubMed Web of Science ®Google Scholar
• Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274(22):1780-2
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Reglan (metoclopramide) tablets, ODT (Orally Disintegrating Tablets), and injection. 2010. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm170934.htm [Last accessed 3 January 2015]
   Google Scholar
• Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997;12(6):952-7
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Domingo-Echaburu S, Soraluce A, et al. Domperidone in Parkinson’s disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf 2013;8(1):63-8
   PubMedGoogle Scholar
• Nishikawa N, Nagai M, Tsujii T, et al. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease. Clin Neuropharmacol 2012;35(4):182-4
   PubMed Web of Science ®Google Scholar
• Roy-Desruisseaux J, Landry J, Bocti C, et al. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011;45(9):e51
   PubMedGoogle Scholar
• Johannes C, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19(9):881-8
   PubMed Web of Science ®Google Scholar
• Van Noord Dieleman JP, van Herpen G, Verhamme K, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010;33(11):1003-14
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Restrictions on the use of domperidone-containing medicines. 2014. Available from: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/European_Commission_final_decision/WC500172573.pdf [Last accessed 2015]
   Google Scholar
• Waseem S, Moshiree B, Draganov PV. Gastroparesis: Current diagnostic challenges and management considerations. World J Gastroenterol 2009;15(1):25-37
   PubMed Web of Science ®Google Scholar
• Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54(4):455-60
   PubMed Web of Science ®Google Scholar
• Janssen P, Harris S, Jones M, et al. The Relation Between Symptom Improvement and Gastric Emptying in the treatment of Diabetic and Idiopathic Gastroparesis. Am J Gastroenterol 2013;108:1382-91
   PubMed Web of Science ®Google Scholar
• Chini P, Toskes PP, Waseem S, et al. Effect of azithromycin on small bowel motility in patients with. Scand J Gastroenterol 2012;47(4):422-7
   PubMed Web of Science ®Google Scholar
• Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322(15):1028-31
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the Risk of Cardiovascular Death. N Engl J Med 2012;366:1881-189
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Meredith S, et al. Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. N Engl J Med 2004;351:1089-96
   PubMed Web of Science ®Google Scholar
• Almalki ZS, Guo JJ. Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. Am Health Drug Benefits 2014;7(6):318-28
   Google Scholar
• Nakatsuka A, Nagai M, Yabe H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients withParkinson’s disease. J Pharmacol Sci 2006;100(1):59-64
   PubMed Web of Science ®Google Scholar
• Doi H, Sakakibara R, Sato M, et al. Nizatidine ameliorates gastroparesis in Parkinson’s disease: a pilot study. Mov Disord 2014;29(4):562-6
   PubMed Web of Science ®Google Scholar
• Futagami S, Shimpuku M, Song JM, et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion 2012;86(2):114-21
   PubMed Web of Science ®Google Scholar
• Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005;22(9):847-53
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010;22(10):1069-e281
   PubMed Web of Science ®Google Scholar
• Wo JM, Ejskjaer N, Hellström PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data. Aliment Pharmacol Ther 2011;33(6):679-88
   PubMed Web of Science ®Google Scholar
• McCallum RW, Lembo A, Esfandyari T, et al. Phase IIb, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(11):e705-17
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Wo JM, Esfandyari T, et al. A phase IIa, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(2):e140-50
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastricemptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36(1):41-8
   PubMed Web of Science ®Google Scholar
• Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson’s disease. Mov Disord 1995;10(1):66-70
   PubMed Web of Science ®Google Scholar
• Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30(1):52-4
   PubMed Web of Science ®Google Scholar
• Moshiree B, Barboza J, Talley N. An update on current pharmacotherapy options for dyspepsia. Expert Opin Pharmacother 2013;14(13):1737-53
   PubMed Web of Science ®Google Scholar
• Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5 HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord 2005;11(8):499-502
   PubMed Web of Science ®Google Scholar
• Krueger D, Gruber L, Buhner S, et al. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil 2009;21(11):1203-e110
   PubMed Web of Science ®Google Scholar
• Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19(3):271-9
   PubMed Web of Science ®Google Scholar
• Schatz RA, Zhang Q, Lodhia N, et al. Predisposing factors for positive D-Xylose breath test for evaluation of small intestinal bacterial overgrowth: A retrospective study of 932 patients. World J Gastroenterol 2015;21(15):4574-82
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013;108(5):707-17
   PubMed Web of Science ®Google Scholar
• Shah SC, Day LW, Somsouk M, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013;38(8):925-34
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008;103(8):2031-5
   PubMed Web of Science ®Google Scholar
• Koo HL, Dupont HL, Huang DB. The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea. Ther Clin Risk Manag 2009;5:841-8
   PubMedGoogle Scholar
• Pimentel M, Lembo A, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Eng J Med 2011;364(1):22-32
   PubMed Web of Science ®Google Scholar
• Furnari M, Parodi A, Gemignani L, et al. Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximinalone in eradicating small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2010;32(8):1000-6
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-19
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13(2):111-16
   PubMed Web of Science ®Google Scholar
• Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006;130(2 Suppl 1):S78-90
   PubMed Web of Science ®Google Scholar
• Marteau P, Shanahan F. Basic aspects and pharmacology of probiotics: an overview of pharmacokinetics, mechanisms of action and side-effects. Best Pract Res Clin Gastroenterol 2003;17:725-40
   PubMed Web of Science ®Google Scholar
• Rosania R, Giorgio F, Principi M, et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol 2013;8(2):169-72
   PubMedGoogle Scholar
• Ojetti V, Ianiro G, Tortora A, et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointestin Liver Dis 2014;23(4):387-91
   PubMed Web of Science ®Google Scholar
• Khalighi AR, Khalighi MR, Behdani R, et al. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth(SIBO)--a pilot study. Indian J Med Res 2014;140(5):604-8
   PubMed Web of Science ®Google Scholar
• Flake ZA, Linn BS, Hornecker JR. Practical selection of antiemetics in the ambulatory setting. Am Fam Physician 2015;91(5):293-6
   PubMed Web of Science ®Google Scholar
• Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-relatedchronic diarrhea. Medicina (B Aires) 2002;62(2):159-63
   PubMed Web of Science ®Google Scholar